TRANSCORNEAL INTRAVITREAL INJECTION TECHNIQUE FOR PEDIATRIC PATIENTS WITH APHAKIA AND POSTVITRECTOMIZED EYES

Poor patient cooperation is thought to be the main issue when attempting to perform intravitreal injection in pediatric patients in the office. Therefore, the authors describe an alternative technique to apply intravitreal injection in an outpatient setting in cases of postvitrectomy aphakic pediatric patients.

[1]  E. Bozkurt,et al.  Factors Associated with Pain Level in Patients Receiving Intravitreal Injection , 2021, Journal of current ophthalmology.

[2]  You-xin Chen,et al.  EFFICACY OF INTRAVITREAL INJECTION OF BEVACIZUMAB IN VITRECTOMY FOR PATIENTS WITH PROLIFERATIVE VITREORETINOPATHY RETINAL DETACHMENT: A Meta-analysis of Prospective Studies , 2017, Retina.

[3]  R. Bansal,et al.  Wandering Ozurdex® implant , 2011, Journal of Ophthalmic Inflammation and Infection.

[4]  Alice Z Chuang,et al.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. , 2011, The New England journal of medicine.

[5]  M. Mura,et al.  Hypotony after 25-gauge vitrectomy. , 2011, American journal of ophthalmology.

[6]  G. Arikan,et al.  Immediate intraocular pressure rise after intravitreal injection of ranibizumab and two doses of triamcinolone acetonide. , 2011, International Journal of Ophthalmology.

[7]  D. D’Amico,et al.  Clinical practice. Primary retinal detachment. , 2008, The New England journal of medicine.

[8]  L. Aiello,et al.  SHORT–TERM EFFECTS OF INTRAVITREAL BEVACIZUMAB FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN PATHOLOGIC MYOPIA , 2007, Retina.

[9]  F. Horozoğlu,et al.  Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. , 2007, American journal of ophthalmology.

[10]  B. Kaderli,et al.  Comparison of Topical and Subconjunctival Anesthesia in Intravitreal Injection Administrations , 2006, European journal of ophthalmology.

[11]  Wuqaas M. Munir,et al.  Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. , 2005, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[12]  J. Pastor,et al.  Proliferative vitreoretinopathy: risk factors and pathobiology , 2002, Progress in Retinal and Eye Research.

[13]  B. Saville,et al.  Drug distribution in the vitreous humor of the human eye: the effects of aphakia and changes in retinal permeability and vitreous diffusivity. , 1997, Journal of Ocular Pharmacology and Therapeutics.